Naoei Yoshitani

RIKEN Center for Integrative Medical Sciences

Papers

1

Total Citations

64

H-Index

1

About

Dr. Naoei Yoshitani has pioneered innovative approaches at the intersection of structural biology and drug discovery, with a primary focus on developing strategies to identify small-molecule ligands for functionally uncharacterized proteins. Their most impactful contribution is a structure-based methodology that integrates *in silico* screening with surface plasmon resonance (SPR) measurements, enabling the rational discovery of small binding compounds for proteins of unknown function—a critical challenge in the postgenomic era. This landmark work, published in 2005 and cited over 60 times, established a powerful pipeline for functional annotation and early-stage drug development. By combining computational predictions with direct biophysical validation, Yoshitani’s approach has provided a template for researchers seeking to bridge the gap between structural genomics and chemical biology. Their work has been instrumental in demonstrating how targeted ligand discovery can unlock the biological roles of orphan proteins, accelerating both basic research and therapeutic target identification. Yoshitani’s contributions continue to influence the design of integrated screening platforms, making them a key figure in the advancement of structure-guided chemical biology.

Research Focus

Key Achievements

1
H-Index
1
Papers
64
Total Citations
64
Avg Citations/Paper
🏆 Most Cited Paper
A structure‐based strategy for discovery of small ligands binding to functionally unknown proteins: Combination of <b><i>in silico</i></b> screening and surface plasmon resonance measurements
64 citations · 2005
📈 Most Prolific Year: 2005 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: RIKEN Center for Integrative Medical Sciences

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago